June 1996 AAOS Report
Board approves Advisory on use of new cell technology
In other action, the Board of Directors approved:
- an Advisory Statement on Cell Tissue Engineered Products.
The Academy advises orthopaedic surgeons that "sound experimental
evidence of safety and efficacy combined with clinical studies
of the new technologies be developed prior to their general use."
The statement also advises that "orthopaedic surgeons should
avoid promoting technologies unless their scientific or clinical
efficacy has been demonstrated."
- construction of a 100- to 110-seat auditorium and additional
facilities in the Orthopaedic Learning Center in Rosemont at a
cost up to $500,000. Academy President Kenneth E. DeHaven,
MD, appointed a work group headed by James D. Heckman,
MD, to develop options for further expansion of the center
and to evaluate the fund-raising potential for further construction
and/or maintenance, replacement and upgrading equipment, and endowment
of the operations of the center. Other members of the work group
are Richard D. Coutts, MD; Richard H. Gelberman, MD; George
L. Lucas, MD; Robert A. Winquist, MD; Joseph D. Zuckerman, MD;
and Mark W. Wieting, director, Academy educational programming.
- a Position Statement on Firearms Violence, which states the
Academy is "committed to reducing death, injury and disability
due to firearm violence through support of a comprehensive public
- limited-use field testing of Phase I and Phase II Low Back
Pain Algorithms which were developed in collaboration with the
North American Spine Society.
- the Academy's fiscal 1997 budget of $34.3 million in
revenues and $33.5 million in expenses.